Vertex Q3 2025 slides: 11% revenue growth as pipeline expands beyond CF
PositiveFinancial Markets

Vertex Pharmaceuticals has reported an impressive 11% revenue growth in Q3 2025, highlighting the expansion of its pipeline beyond cystic fibrosis (CF). This growth is significant as it indicates the company's successful diversification and innovation in developing new treatments, which could lead to improved patient outcomes and increased market presence.
— Curated by the World Pulse Now AI Editorial System













